Mathematically modelling the dynamics of cholesterol metabolism and ageing

A E Morgan1, K M Mooney2, S J Wilkinson1

  • 1Department of Chemical Engineering, University of Chester, Thornton Science Park, Chester, CH2 4NU, United Kingdom.

Bio Systems
|May 10, 2016
PubMed

Insights

Mathematical modeling reveals how aging impacts cholesterol metabolism. Specific cholesterol ester transfer protein (CETP) genotypes influence low-density lipoprotein cholesterol (LDL-C) levels, highlighting their role in healthy aging and cardiovascular disease risk.

Area of Science:

  • Biomedical Engineering
  • Computational Biology
  • Gerontology

Background:

  • Cardiovascular disease (CVD) is a primary cause of death in the UK, with prevalence increasing significantly in individuals over 75.
  • Cholesterol metabolism dysregulation is closely linked to CVD, making LDL-C and HDL-C key risk biomarkers.
  • Aging exacerbates cardiovascular issues, necessitating a deeper understanding of its impact on cholesterol regulation.

Purpose of the Study:

  • To mathematically model and explore the effects of aging on whole-body cholesterol metabolism.
  • To investigate how different cholesterol ester transfer protein (CETP) genotypes interact with aging to affect cholesterol levels.
  • To identify potential targets for intervention to promote healthy aging and reduce CVD risk.

Main Methods:

  • An existing whole-body mathematical model of cholesterol metabolism was updated with 96 additional biological mechanisms.
  • The enhanced model incorporated detailed processes of cholesterol absorption, synthesis, reverse cholesterol transport (RCT), and bile acid metabolism.
  • Model sensitivity was analyzed using parameter scans, and regulatory mechanisms were tested with acute cholesterol feeding simulations.

Main Results:

  • The model demonstrated a hypo-responsive behavior to cholesterol feeding, with significant increases observed in hepatic and intestinal cholesterol pools.
  • Simulations indicated that aging, combined with a low-activity CETP genotype, led to a 0.6% increase in LDL-C.
  • Aging with a high-activity CETP genotype resulted in a more substantial 1.6% increase in LDL-C.

Conclusions:

  • Mathematical modeling provides valuable insights into the complex interplay between aging, cholesterol metabolism, and CVD risk.
  • CETP genotypes, such as I405V, play a crucial role in modulating LDL-C levels during aging.
  • Understanding these genetic influences is vital for developing personalized strategies for healthy aging and cardiovascular disease prevention.

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
314
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
334
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
4.1K
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
319
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
368